Table 8 Patients and tumor caracteristics of the selected studies Kidney and target therapy
From: Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Authors (year of publication) [reference] | Number of patients underwent SBRT | Type of Study | Primary Tumor site | Number of metastases underwent to SBRT | Type of oligometastases and organ involved (liver, lung, bone, nodes, brain…) | Metastases size (cm) | Median total dose/fraction | BED (Median value) | Systemic Therapy |
|---|---|---|---|---|---|---|---|---|---|
Staehler 2011 [57] | 106 | Retrospective | Kidney | N.S. | Spinal (55 pts) Brain (51 pts) | in cm3 spinal: 30.1 brain: 1.7 | 20 Gy in single fraction | N.S. | Sunitinib (45 pts) Sorafenib (61 pts) |
Staehler 2012 [58] | 22 | Prospective | Kidney | N.S. | Progressive RCC in brain, retroperitoneal mediastinal lymph nodes, spinal cord, bones, liver, and kidney | N.S. | 40 Gy in 8 fr (5Gy/fraction)a | N.S. | Sunitinib |
Cochran 2012 [50] | 61 (24 pts. received target therapy) | Retrospective | Kidney | N.S. | Brain | N.S. | 20 Gy in single fraction | N.S. | TKIs, mTORIs, or bevacizumab (24 pts) |
Verma 2013 [51] | 81 (40 pts. received target therapy) | Retrospective | Kidney | 216 | Brain (at diagnosis and at relapse) | N.S. | SRS in 89 lesionsc | N.S. | TKIs (40 pts) |
Bastos 2015 [59] | 65 | Retrospective | Kidney | SRTb (41 pts) | Brain (54% of pts. more than 1 met) | N.S. | N.S. | N.S. | antiangiogenetic (anti-VEGF, temsirolimus, sorafenib, bevacizumab, everolimus, pazopanib, axitinib) (53 pts) mTORIs (12 pts) |
Miller 2016 [54] | 100 (46 pts. received target therapy) | Retrospective | Kidney | N.S. | Spine | N.S. | 16 Gy in 1 fraction | N.S. | TKI |
Franzese 2019 [55] | 58 (38 pts. received target therapy) | Retrospective | Kidney | 73 | Extracranial oligometastases | 2.6 cm (diameter) | 45 Gy in 5 fractions (9Gy/fraction) | N.S. | TKI or “other target therapies” (28 pts. received therapy before and 17 pts. – during SRT) |